共查询到20条相似文献,搜索用时 54 毫秒
1.
2.
Comparison of abluminal biodegradable polymer biolimus‐eluting stents and durable polymer everolimus‐eluting stents in the treatment of coronary bifurcations
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Charis Costopoulos MD Azeem Latib MD Toru Naganuma MD Alessandro Sticchi MD Santo Ferrarello MD Damiano Regazzoli MD Alaide Chieffo MD Filippo Figini MD Mauro Carlino MD Matteo Montorfano MD Charbel Naim MD Masanori Kawaguchi MD Argyrios Gerasimou MD Francesco Giannini MD Cosmo Godino MD Antonio Colombo MD 《Catheterization and cardiovascular interventions》2014,83(6):889-895
3.
Moritz Baquet MD David Jochheim MD Julinda Mehilli MD 《Journal of interventional cardiology》2018,31(3):330-337
4.
Two‐year clinical outcomes of the NOBORI biolimus‐eluting stents versus XIENCE/PROMUS everolimus‐eluting stents in small vessel disease
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hiroyuki Jinnouchi MD Shoichi Kuramitsu MD Tomohiro Shinozaki MPH Takashi Hiromasa MD Yohei Kobayashi MD Takashi Morinaga MD Kyohei Yamaji MD Yoshimitsu Soga MD Shinichi Shirai MD Kenji Ando MD 《Catheterization and cardiovascular interventions》2016,88(5):E132-E138
5.
Sean M. Conte Daniel S. Florisson Joshua A. De Bono Peter R. Vale 《Internal medicine journal》2019,49(12):1534-1537
A best evidence topic was written addressing the question ‘in patients with saphenous vein graft lesions requiring percutaneous coronary intervention, do long‐term clinical outcomes differ between drug‐eluting and bare‐metal stents?’ Altogether 1466 papers were found, of which seven represented the best evidence. Although one major recent randomised trial was neutral, the weight of earlier evidence supports drug‐eluting stents as standard of care. Bare‐metal stents may represent a reasonable, efficacious, and less expensive alternative to drug‐eluting stents in well selected patient groups. 相似文献
6.
7.
8.
9.
Safety and efficacy profile of bioresorbable‐polylactide‐polymer‐biolimus‐A9‐eluting stents versus durable‐polymer‐everolimus‐ and zotarolimus‐eluting stents in patients with acute coronary syndrome
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Milosz Jaguszewski MD PhD Manuela Dörig Antonio H. Frangieh MD Jelena‐Rima Ghadri MD Victoria Lucia Cammann Johanna Diekmann L. Christian Napp MD Fabrizio D'Ascenzo MD Yoichi Imori MD Slayman Obeid MD Willibald Maier MD Thomas F. Lüscher MD Christian Templin MD PhD 《Catheterization and cardiovascular interventions》2016,88(6):E173-E182
10.
11.
12.
13.
Michael S. Lee MD Raymond Zimmer MD Antonio Pessegueiro MD Daniel Jurewitz MD Jonathan Tobis MD 《Catheterization and cardiovascular interventions》2008,71(4):526-530
Background : Age is an important predictor of mortality after percutaneous coronary intervention (PCI). The safety and efficacy of PCI with drug‐eluting stents (DES) in nonagenarians have not been extensively studied. Methods : A retrospective analysis of 889 consecutive patients identified 28 (3.1%) nonagenarians who underwent PCI with DES from May 2003 to December 2005 at our institution. Results : The mean age was 92 ± 2 years, 39% were male, and 4% were diabetic. Sirolimus‐eluting stents were used in 79%. A mean of 1.5 ± 0.9 stents/patient were implanted with a total stent length of 31 ± 20 mm. Twenty‐nine percent presented with unstable angina and 39% with myocardial infarction. The angiographic success rate obtained was 100%. The 30‐day mortality rate was 21%. The 6 patients who died within 30 days included 3 patients who had cardiogenic shock and one patient with critical aortic stenosis who died due to complications during percutaneous aortic valvuloplasty. The cumulative survival rate for all nonagenarians at 1 year and 3 years was (68 ± 9)% and (61 ± 9)%. When the four patients who were in extremis on presentation were excluded, there were no in‐hospital deaths, the 30‐day mortality was 8%, and the 1 year and 3 year survival rate was (79 ± 8)% and (71 ± 9)% for the nonagenarians. No patient had definite stent thrombosis. Conclusions : The majority of the nonagenarians who underwent PCI with DES presented with acute coronary syndrome. Percutaneous coronary intervention with DES was safe in nonagenarians as there were no in‐hospital deaths and acceptable 3‐year survival rates when patients who were in extremis on presentation were excluded. The high‐risk profile of these patients and the expected attrition of nonagenarians may contribute to their mortality rates. © 2008 Wiley‐Liss, Inc. 相似文献
14.
Rationale and design of amphilimus sirolimus‐eluting stents versus zotarolimus‐eluting stents in all‐comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rik Rozemeijer MD MSc Mèra Stein MD PhD Peter Frambach MD Michiel Voskuil MD PhD Adriaan O. Kraaijeveld MD PhD Ramón Rodríguez‐Olivares MD Leo Timmers MD PhD Bruno Pereira MD Saskia Z. Rittersma MD PhD Pierfrancesco Agostoni MD PhD Pieter A. Doevendans MD PhD FESC Pieter R. Stella MD PhD 《Catheterization and cardiovascular interventions》2018,91(3):410-416
15.
Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxel‐eluting stents: Two‐year clinical outcomes of paclitaxel‐eluting stents in patients from the ARRIVE program
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Michael S. Lee MD Tae Yang MD John Lasala MD David Cox MD 《Catheterization and cardiovascular interventions》2016,88(6):891-897
16.
Antonio Montefusco Fabrizio D'Ascenzo Sebastiano Gili Grzegorz Smolka Alaide Chieffo Andreas Baumbach Javier Escaned Paolo Sganzerla Francesco Tomassini Gioel Gabrio Secco Fabrizio Ugo Corrado Tamburino Annamaria Nicolino Massimo Mancone Arnaldo Poli Kuan‐Leong Yew Plinio Cirillo Wojciech Wanha Luigi Emilio Pastormerlo Roberto di Summa Gennaro Sardella Antonio Colombo Fiorenzo Gaita Bernardo Cortese 《Catheterization and cardiovascular interventions》2019,93(2):208-215
17.
Sebastian Kufner Steffen Massberg Michael Dommasch Robert A. Byrne Klaus Tiroch Sabine Ranftl Massimiliano Fusaro Albert Schmig Adnan Kastrati Julinda Mehilli 《Catheterization and cardiovascular interventions》2011,78(2):161-166
Background : In the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus‐Eluting Stents (ISAR‐TEST‐4) trial, we demonstrated the noninferiority of biodegradable polymer (BP) sirolimus‐eluting stent to permanent polymer (PP) sirolimus/everolimus‐eluting stent (Cypher/Xience‐V) on the basis of clinical outcomes. In this study, we compare the antirestenotic efficacy of these stents in ISAR‐TEST‐4 patients with paired angiographic studies. Methods : Patients with de novo coronary lesions in native vessels (excluding left main lesions) were randomly assigned to receive a BP stent or a PP stent. Endpoints of interest of this study were in‐stent late lumen loss, in‐segment binary restenosis, and restenosis morphology at 6–8‐month follow‐up angiogram. Results : Of the 2,603 patients (3,372 lesions) enrolled in ISAR TEST‐4 trial, 2,016 patients (2,637 lesions) underwent repeat angiographic examination 6–8 months after randomization: 1,006 patients (1,323 lesions) treated with BP stents and 1,010 patients (1,314 lesions) treated with PP stents. No difference was observed between BP and PP stents in in‐stent late lumen loss (0.24 ± 0.6 vs. 0.26 ± 0.5 mm, respectively, P = 0.49) or in in‐segment binary restenosis (11.6% [153 lesions] vs. 11.8% [155 lesions], P = 0.85). Focal pattern of restenosis was observed in the majority of patients receiving either BP or PP stents. The diffuse pattern of restenosis was observed in 26.8% of patients treated with BP stent and 26.5% of patients treated with PP stent (P = 0.79). Conclusion : Angiographic characteristics of restenosis after BP‐based limus‐eluting stents are similar to those of PP‐based limus‐eluting stents. © 2011 Wiley‐Liss, Inc. 相似文献
18.
Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir‐based polymer‐free amphilimus‐eluting stents versus everolimus‐eluting stents with durable polymer in patients with diabetes mellitus
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
R. Romaguera MD S. Brugaletta MD PhD J. Gomez‐Lara MD PhD E. Pinar MD P. Jiménez‐Quevedo MD M. Gracida MD G. Roura MD J.L. Ferreiro MD L. Teruel MD J.A. Gómez‐Hospital MD PhD E. Montanya MD F. Alfonso MD M. Valgimigli MD M. Sabate MD PhD A. Cequier MD PhD 《Catheterization and cardiovascular interventions》2015,85(4):E116-E122
19.
Vijay S. Ramanath MD Jeremiah R. Brown PhD David J. Malenka MD James T. DeVries MD Mandeep S. Sidhu MD MBA John F. Robb MD John E. Jayne MD Bruce D. Hettleman MD Bruce J. Friedman MD Nathaniel W. Niles II MD Aaron V. Kaplan MD Craig A. Thompson MD MMSc 《Catheterization and cardiovascular interventions》2010,76(4):473-481
Objectives : We sought to determine if differences existed in in‐hospital outcomes, long‐term rates of target vessel revascularization (TVR), and/or long‐term mortality trends between patients with diabetes mellitus undergoing percutaneous coronary intervention (PCI) with either a drug‐eluting stent(s) (DES) or a bare metal stent(s) (BMS). Background : Short‐ and long‐term clinical outcomes of patients with diabetes mellitus undergoing PCI with DES versus BMS remain inconsistent between randomized‐controlled trials (RCTs) and observational studies. Methods : Data were collected prospectively on diabetics undergoing PCI with either DES or BMS from January 2000 to June 2008. Demographic information, medical histories, in‐hospital outcomes, and long‐term TVR and mortality trends were obtained for all patients. Results : A total of 1,319 patients were included in the study. Diabetics receiving DES had a significant reduction in index admission MACE compared to diabetics receiving BMS. Using multivariable adjustment, after a mean follow‐up of 2.5 years (maximum 5 years), diabetics who received DES had a 38% decreased risk of TVR compared to diabetics with BMS [HR 0.62 (95% CI: 0.43–0.90)]; diabetics with DES had an insignificant adjusted improvement in long‐term survival compared to diabetics with BMS [HR 0.72 (95% CI: 0.52–1.00)]. These long‐term survival and TVR rates were confirmed using propensity scoring. Conclusions : The use of DES when compared with BMS among diabetics undergoing PCI is associated with significant improvement in long‐term TVR, with an insignificant similar trend in all‐cause mortality. The long‐term results of this observational study are consistent with prior RCTs after adjusting for confounding variables. © 2010 Wiley‐Liss, Inc. 相似文献